(Q43807978)

27 November 2017

Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection (English)

1 reference

27 November 2017

1 reference

1 reference

1 reference

1 reference

Pohl A

1

1 reference

27 November 2017

Behling C

2

1 reference

27 November 2017

Oliver D

3

1 reference

27 November 2017

Kilani M

4

1 reference

27 November 2017

Monson P

5

1 reference

27 November 2017

Hassanein T

6

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

The American Journal of Gastroenterology

27 November 2017

1 reference

27 November 2017

96

1 reference

27 November 2017

11

1 reference

27 November 2017

3142-3146

1 reference

Enhancing the response to interferon-alpha.

27 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05268.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05268.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05268.X

Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05268.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05268.X

Treatment of patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05268.X

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05268.X

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05268.X

Progressive liver functional impairment is associated with an increase in AST/ALT ratio.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05268.X

AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05268.X

AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05268.X

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.05268.X

10.1111/J.1572-0241.2001.05268.X

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference